Navigation Links
Tumors evolve rapidly in a childhood cancer, leaving fewer obvious tumor targets
Date:1/20/2013

An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutationsmutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.

"This research underscores the fact that tumor cells often change rapidly over time, so more effective treatments for this aggressive cancer will need to account for the dynamic nature of neuroblastoma," said study leader John M. Maris, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP).

Striking the peripheral nervous system, neuroblastoma usually appears as a solid tumor in a young child's chest or abdomen. It comprises 7 percent of all childhood cancers, but causes 10 to 15 percent of all childhood cancer-related deaths. Neuroblastoma is notoriously complex, with a broad number of gene changes that can give rise to the disease.

Maris headed the multicenter research collaborative, the TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative, which released its findings today in Nature Genetics. This largest-ever study genomic study of a childhood cancer analyzed DNA from 240 children with high-risk neuroblastomas. Using a combination of whole-exome, whole-genome and transcriptome sequencing, the study compared DNA from tumors with DNA in normal cells from the same patients.

Researchers at CHOP and other centers previously discovered neuroblastoma-causing mutations, such as those in the ALK gene. In the subset of patients carrying this mutation, oncologists can provide effective treatments tailored to their genetic profile.

"A few years ago, we thought we would be able to sequence the genome
'/>"/>

Contact: Rachel Salis-Silverman
salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. TGen leads new National Institutes of Health study of brain tumors
3. A single stem cell mutation triggers fibroid tumors
4. Cancerous tumors deliver pro-metastatic information in secreted vesicles
5. Breast cancer drug could halt other tumors
6. Researchers identify proteins that indicate which kidney tumors are most likely to spread
7. Cancer stem cells isolated from kidney tumors
8. Study uncovers mechanism used by BRCA1 to suppress tumors
9. Leading evolutionary scientist to discuss how genome of bacteria has evolved
10. Excessive worrying may have co-evolved with intelligence
11. Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with the 2015 ... of the Year Award. Credence ID has developed ... its mission of offering enrollment and identification solutions ... Credence ID was formed by experts from the ...
(Date:7/2/2015)... , June 25, 2015 ... announced the addition of the "Natural Language ... Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... their offering. The key vendors occupying ... HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, SAS ...
(Date:7/2/2015)... July 2, 2015 Fingerprint Cards has ... FPC1145 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... will be used by smartphone manufacturers in Asia ... in the communicated revenue guidance of approximately 2,200 MSEK for ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... Like a family of petty criminals gone wrong, researchers ... surprised to find that bacterial pathogens found in a ... only that, their wrong-doing is carried out by disguising ... Ph.D., Dean for Scientific Affairs and Professor of Pharmacology ...
... the Universtity of Helsinki, Finland, came together to advance ... controlled. The results of this work are published in ... reached in 2001 when sequencing of the human genome ... read-outs of DNA sequence for several species, for example ...
... have discovered a cluster of 45 genes coding ... baumannii, a major cause of hospital-acquired infections worldwide. ... journal PLoS Genetics. , "We expected to find ... at the Structural and Genomic Information Laboratory at ...
Cached Biology News:UCSD team unmasks family of immune system invaders 2UCSD team unmasks family of immune system invaders 3Cracking the genetic code for control of gene expression 2Supersized 'island' of resistance genes discovered in an infectious bacterium 2
(Date:7/29/2015)... CT (PRWEB) , ... July 29, 2015 , ... ... Biological Industries’ (BI) advanced cell culture products, announces the availability of BI’s line ... launched by Biological Industries, these stem cell differentiation media offer a complete system ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials ... wide range of liquid viscosities – from less than 12,000 mPas (internal air) up to ... , What immediately catches the eye about Xsample 530 is its removable magazine, which ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
Breaking Biology Technology:Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2
... (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... , , ... ... ...
... ... Be Discussed and Demonstrated at Philadelphia Conference , ... Chicago, IL (PRWEB) March 11, 2010 -- ClearTrial, the ... panel discussion which includes pharmaceutical analysts from Deutsche Bank and Cowen & Company at ...
... TORONTO , March 11 /PRNewswire/ - Trillium Therapeutics ... announced that it has entered into two definitive license agreements ... Children (SickKids) in Toronto, Ontario , granting Trillium exclusive ... of hematopoietic stem cell transplantation and cancer. , ...
Cached Biology Technology:Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 2ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress 3Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: